Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price ...
AZN's Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major ...
Italian drive to increase diagnosis rates in children with severe genetic disorders is achieving transformative results. The ...
Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...
Former Speaker Paul Ryan is joining the strategic advisory board for defense tech startup EdgeRunner AI, our colleague Tyler ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results